IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) Meeting Abstract
| Authors: | Hussain, M. H. A.; Powles, T.; Albers, P.; Castellano, D.; Daneshmand, S.; Gschwend, J.; Nishiyama, H.; Oudard, S.; Tayama, D.; Davarpanah, N. N.; Degaonkar, V.; Shi, Y.; Mariathasan, S.; Grivas, P.; O'Donnell P. H.; Rosenberg, J. E.; Geynisman, D. M.; Hoffman-Censits, J. H.; Petrylak, D. P.; Bellmunt, J. |
| Abstract Title: | IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 277s |
| Language: | English |
| ACCESSION: | WOS:000560368302257 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.5000 |
| Notes: | Meeting Abstract: 5000 -- Source: Wos |
